- Dec 15, 2016
NCT02649790: Phase 1/2: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Cancer
RRMM Relapsed Refractory Multiple Myeloma NCT02649790: Phase 1/2: Study of the Safety, Tolerability and Efficacy of KPT-8602 in...
82
- Dec 18, 2015
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
STOMP Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP) This study will independently assess the efficacy and safety...
410
- Dec 17, 2014
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple...
41
- Dec 20, 2013
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory MM
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma The phase 1 primary...
123
- Dec 11, 2013
NCT01857115: Phase 1/2: EMN - Study of Wkly Carfilzomib, Cyclophosphamide and Dexamethasone In NDMM
wCCyd EMN European Myeloma Network NCT01857115: Phase 1/2: Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly...
107
- Dec 11, 2013
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic...
65